Regeneron Shareholders Back Directors, Auditor and Executive Pay
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
The latest update is out from Regeneron ( (REGN) ).
At its 2026 Annual Meeting of Shareholders held on June 12, 2026, Regeneron shareholders elected five Class II directors, including Joseph L. Goldstein, Christine A. Poon, David P. Schenkein, Craig B. Thompson and Huda Y. Zoghbi, to serve until the 2027 Annual Meeting and until their successors are duly elected and qualified. Shareholders also ratified the appointment of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026 and approved, on an advisory basis, the compensation of the company’s named executive officers, signaling broad investor support for the current board composition, governance approach and executive pay practices.
The most recent analyst rating on (REGN) stock is a Buy
with a $855.00 price target.
To see the full list of analyst forecasts on Regeneron stock,
see the REGN Stock Forecast page.
Spark’s Take on REGN Stock
According to Spark, TipRanks’ AI Analyst, REGN is a Outperform.
The score is driven primarily by strong financial performance (durable profitability, strong free cash flow, and a conservative balance sheet) and a generally constructive earnings-call outlook with clear growth drivers and capital returns. These strengths are tempered by weak near-term technical momentum and some business/regulatory headwinds (legacy EYLEA pressure and temporary manufacturing/regulatory timing issues), while valuation appears fair but not strongly supported by yield.
To see Spark’s full report on REGN stock,
click here.
More about Regeneron
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing and commercializing medicines for serious diseases. The company operates in the biopharmaceutical industry, targeting areas such as ophthalmology, oncology, immunology and rare diseases, and is a major player in the U.S. and global prescription drug markets.
Average Trading Volume: 894,714
Technical Sentiment Signal: Sell
Current Market Cap: $64.47B
For a thorough assessment of REGN stock, go to TipRanks’ Stock Analysis page.
